A Phase 2 interventional study of Dexmedetomidine and Placebo in Insomnia, sponsored by Woolcock Institute of Medical Research. Recruiting at 1 site in Australia. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Woolcock Institute of Medical Research · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing dexmedetomidine in Sleep Initiation and Maintenance Disorders — 1 open to participants now, 1 under way, none of them phase 3. Dexmedetomidine · Sleep Initiation and Maintenance Disorders.
Among the 12 studies testing dexmedetomidine in Sleep Initiation and Maintenance Disorders, this one is the 9th largest by planned enrollment, is the only one that started in 2026, is the only one in phase 2, and was the 12th registered.
2,728 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →1 of the 12 studies testing dexmedetomidine in Sleep Initiation and Maintenance Disorders is open now, in 1 country.
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.
This study: 30 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 1 · Phase 4 6
First in 2014; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 68 across 2,356 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 72 across the 12 interventional studies. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 6 most frequent:
Woolcock Institute of Medical Research is the lead sponsor of 17 studies on the registry; 12 are open to participants now.
10 studies in Sleep Initiation and Maintenance Disorders by Woolcock Institute of Medical Research: 7 open now, 7 under way, none of them phase 3. Of 3 finished, 0 (0%) have results posted.
Among the 10 studies in Sleep Initiation and Maintenance Disorders by Woolcock Institute of Medical Research, this one is the 8th largest by planned enrollment, is one of 3 that started in 2026, is one of 2 in phase 2, and was the 10th registered.
Woolcock Institute of Medical Research’s Sleep Initiation and Maintenance Disorders studies by the year they started, since 2022.
1 of the studies testing dexmedetomidine in Sleep Initiation and Maintenance Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07392177Woolcock Institute of Medical ResearchUnderstanding the Role of the Locus Coeruleus in Insomnia | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing dexmedetomidine in Sleep Initiation and Maintenance Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Woolcock Institute of Medical Research’s 10 in Sleep Initiation and Maintenance Disorders:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This research project aims to better understand the neurobiological mechanistic underpinnings of insomnia disorder. The main question is whether cortical hyperarousal in individuals with insomnia disorder, measured by electroencephalograhic (EEG) infraslow oscillation coupling of sigma power during non-rapid eye movement (NREM) sleep and theta power during rapid eye movement (REM) sleep, is related to locus coeruleus activity.
This trial is a double-blinded, placebo-controlled, randomised controlled cross over trial of dexmedetomidine or placebo in adults with insomnia disorder. Participants will be recruited using social media, bulletin boards and patient referrals from the Woolcock Institute of Medical Research clinics. Participants will be asked to complete an online pre-screening webpage (RedCap) to check for eligibility, and provided with the Participant Information Sheet (PIS) and asked for contact details for an in-person screening visit. The participants will have the study explained in detail during the screening visit followed by written informed consent. The participant will then undergo a medical screening for diagnosis of insomnia disorder and the medical officer will sign the consent form. Thereafter, the participant will complete baseline questionnaires and be randomised to either dexmedetomidine or placebo for the 2 sleep laboratory visits. Participants will then be instructed to maintain their regular sleep-wake patterns for seven days before the first sleep laboratory visit (Visit 1). During Visit 1, participants will undergo a number of assessments (pre-sleep locus coeruleus activity measured using pupillometry, electroencephalography (EEG), functional near-infrared spectroscopy (fNIRS) before and during sleep and questionnaires about subjective hyperarousal. Participants will receive either dexmedetomidine or placebo. Following Visit 1, participants will have a 14-day washout, before Visit 2, which will repeat the procedures of Visit 1, but participants will receive the alternate condition (placebo or dexmedetomidine). The study will be coordinated from the Woolcock Institute of Medical Research, Sydney, Macquarie University, NSW, 2113, Australia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 96 µg dexmedetomidine tablet taken during the sleep laboratory visit only
Drug: Dexmedetomidine
Matching placebo tablet taken during the sleep laboratory visit only
Drug: Placebo
A buccal tablet containing 96 µg dexmedetomidine will be taken before habitual bedtime.
Placebo tablets will contain identical excipient without the active ingredient (dexmedetomidine) and manufactured under the same condition as the active. Placebo tablets, packs and instructions will be identical in every respect to enable the double-blind study design.
Electrographic (EEG) signatures
Electrographic (EEG) infraslow oscillations (\~50 sec) of sigma power and sleep spindle coupling during non-rapid eye movement (NREM) sleep and theta power during rapid eye movement (REM) sleep.
Time frame: Baseline and 14 days
Sleep Fragmentation
Polysomnography (PSG) measure conducted during the intervention and control (wake after sleep onset)
Time frame: Baseline and 14 days
EEG power
Electroencephalographic (EEG) power during non-rapid eye movement (NREM) (stages 2 and 3) and rapid eye movement (REM) sleep. Unit of measurement is μV\^2.
Time frame: Baseline and 14 days
Neurovascular activity (fNIRS)
Measurement of global blood flow using functional near-infrared spectroscopy (fNIRS).
Time frame: Baseline and 14 days
Cardiopulmonary Coupling (CPC)
Cardiopulmonary coupling provides a global measure of autonomic function
Time frame: Baseline and 14 days
Pupillometry
Pupil sizes will be assessed as a surrogate of locus coeruleus activity
Time frame: Baseline and 14 days
Subjective hyperarousal
Pre-Sleep Arousal Scale (PSAS) before sleep. Scored by summing 16 items (rated 1 (not at all) to 5 (extremely)) with a total score between 16 to 80
Time frame: Baseline and 14 days
Subjective sleep quality
Self-reported rating of sleep quality (0-9) with higher scores indicating worse sleep. This will assessed in the morning after the overnight sleep study.
Time frame: Baseline and 14 days
Plan to share: Yes — Non-identifiable IPD will be shared upon reasonable request to the Principal Investigators.
Supporting information: Study protocol, Informed consent form, Analytic code
Time frame: Non-identifiable IPD will become available one year after the Actual Study Completion Date and will be available for ten years.
Access criteria: A copy of the non-identifiable dataset may be requested by academic collaborators not affiliated with the Woolcock Institute of Medical Research through a data request form which outlines the investigators, aims and hypotheses, data to be included, a statistical analysis plan, ethics approval, and security measures. Contact the Coordinating Principal Investigator for access to data.
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Mar 2027, 7 months after the start.
Of 63 phase 2 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 7 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
Sleep Initiation and Maintenance Disorders →
Woolcock Institute of Medical Research